ASX AnnouncementsPatrys demonstrates potential for deoxmabs in antibody drug conjugates (ADCs)15 Sep 20210Today Patrys announced new data from a successful preclinical study highlighting the potential for using our deoxymab antibodies as targeting…
MediaBioshares | August 202126 Aug 20210Patrys has been featured in the latest edition of investor newsletter Bioshares. Bioshares has previously focused on the unmet needs…
ASX AnnouncementsPatrys FY21 Annual Report25 Aug 20210Patrys has today released its Annual Report for the 2020-2021 Financial Year (FY21). Highlights include: 2020 Expansion of deoxymab portfolio…
ASX AnnouncementsQUARTERLY ACTIVITIES REPORT & 4C29 Jul 20210Patrys has today released its Quarterly Activities Report and 4C for the quarter ended 30 June 2021. Our R&D program…
ASX AnnouncementsPAT-DX1 Significantly Improves Survival in Animal Model of Pancreatic Cancer26 Jul 20210New preclinical data from the Garvan Institute of Medical Research has shown that Patrys’ deoxymab antibody PAT-DX1 is able to…
ASX AnnouncementsNew data shows PAT-DX3 able to cross the blood brain barrier12 Jul 20210In an exciting development, Patrys today announced new data confirming its full-sized IgG deoxymab antibody, PAT-DX3, is able to cross…
News UpdateBioshares | June 20211 Jul 20210Patrys has been featured in the latest edition (Edition 896) of investor newsletter Bioshares. The article highlights our Company’s strong…
MediaPatrys in The Australian16 Jun 20210Patrys appears on page 7 of The Australian today as part of a story secured with the newspaper’s Health Editor,…
ASX AnnouncementsNew Data | PAT-DX115 Jun 20210Patrys is pleased to announce the publication of new data in the highly-regarded Journal of Clinical Investigation – Insight, demonstrating…
NewsletterNewsletter | June 20216 Jun 20210Patrys is pleased to share its latest Newsletter, published June 2021. Key highlights: Letter from our CEO Media and analyst…